Appropriate Polypharmacy and Medicine Safety: When Many is not Too Many

Drug Safety

Volumn 39, Issue 2, 2016, Pages 109-116

  Cadogan, Cathal A ^a,b   Ryan, Cristín ^a,b   Hughes, Carmel M ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

APPROPRIATE PRESCRIBING; ARTICLE; CLINICAL PRACTICE; CLINICAL RESEARCH; DRUG SAFETY; HUMAN; MEDICINE; PATIENT RISK; PATIENT SAFETY; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RESEARCH; AGED; DRUG INTERACTION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; INAPPROPRIATE PRESCRIBING; MIDDLE AGED; STANDARDS; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DRUG INTERACTIONS; DRUG PRESCRIPTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INAPPROPRIATE PRESCRIBING; MIDDLE AGED; PATIENT SAFETY; POLYPHARMACY;

EID: 84957070788     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-015-0378-5     Document Type: Article

References (53)

1. Sumukadas D, McMurdo ME, Mangoni AA, Guthrie B. Temporal trends in anticholinergic medication prescription in older people: repeated crosssectional analysis of population prescribing data. Age Ageing. 2014;43(4):515–21.
2. Hovstadius B, Hovstadius K, Astrand B, Petersson G. Increasing polypharmacy: an individual-based study of the Swedish population 2005–2008. BMC Clin Pharmacol. 2010;10:16.
3. Franchi C, Tettamanti M, Pasina L, Djignefa CD, Fortino I, Bortolotti A, et al. Changes in drug prescribing to Italian community-dwelling elderly people: The EPIFARM-Elderly Project 2000–2010. Eur J Clin Pharmacol. 2014;70(4):437–43.
4. Hughes C, Cooper JA, Ryan C. Going beyond the numbers: a call to redefine polypharmacy. Br J Clin Pharmacol. 2014;77(6):915–6.
5. Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug–drug interactions: population database analysis 1995–2010. BMC Med. 2015;13:74.
6. Akbarov A, Kontopantelis E, Sperrin M, Stocks SJ, Williams R, Rodgers S, et al. Primary care medication safety surveillance with integrated primary and secondary care electronic health records: a cross-sectional study. Drug Saf. 2015;38(7):671–82.
7. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug–drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289(13):1652–8.
8. Leendertse AJ, Egberts ACG, Stoker LJ, van den Bemt PMLA. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med. 2008;168(17):1890–6.
9. Payne RA, Avery AJ. Polypharmacy: one of the greatest prescribing challenges in general practice. Br J Gen Pract. 2011;61(583):83–4.
10. Patterson S, Cadogan C, Kerse N, Cardwell C, Bradley M, Ryan C, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2014;10:CD008165.
11. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57–65.
12. Aronson JK. In defence of polypharmacy. Br J Clin Pharmacol. 2004;57(2):119–20.
13. Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN. Polypharmacy: misleading, but manageable. Clin Interv Aging. 2008;3(2):383–9.
14. Cahir C, Fahey T, Teeling M, Teljeur C, Feely J, Bennett K. Potentially inappropriate prescribing and cost outcomes for older people: a national population study. Br J Clin Pharmacol. 2010;69(5):543–52.
15. Bradley MC, Fahey T, Cahir C, Bennett K, O’Reilly D, Parsons C, et al. Potentially inappropriate prescribing and cost outcomes for older people: a cross-sectional study using the Northern Ireland Enhanced Prescribing Database. Eur J Clin Pharmacol. 2012;68(10):1425–33.
16. Rollason V, Vogt N. Reduction of polypharmacy in the elderly: a systematic review of the role of the pharmacist. Drugs Aging. 2003;20(11):817–32.
17. Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C, et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet. 2007;370(9582):173–84.
18. Kaufmann CP, Tremp R, Hersberger KE, Lampert ML. Inappropriate prescribing: a systematic overview of published assessment tools. Eur J Clin Pharmacol. 2014;70(1):1–11.
19. Cherubini A, Corsonello A, Lattanzio F. Underprescription of beneficial medicines in older people. Drugs Aging. 2012;29(6):463–75.
20. Kuijpers MAJ, van Marum RJ, Egberts ACG, Jansen PAF. Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol. 2008;65(1):130–3.
21. Galvin R, Moriarty F, Cousins G, Cahir C, Motterlini N, Bradley M, et al. Prevalence of potentially inappropriate prescribing and prescribing omissions in older Irish adults: findings from The Irish LongituDinal Study on Ageing study (TILDA). Eur J Clin Pharmacol. 2014;70(5):599–606.
22. Hancock HC, Close H, Fuat A, Murphy JJ, Hungin APS, Mason JM. Barriers to accurate diagnosis and effective management of heart failure have not changed in the past 10 years: a qualitative study and national survey. BMJ Open. 2014;4(3):e003866.
23. Payne RA, Abel GA, Avery AJ, Mercer SW, Roland MO. Is polypharmacy always hazardous? A retrospective cohort analysis using linked electronic health records from primary and secondary care. Br J Clin Pharmacol. 2014;77(6):1073–82.
24. Appleton SC, Abel GA, Payne RA. Cardiovascular polypharmacy is not associated with unplanned hospitalisation: evidence from a retrospective cohort study. BMC Fam Pract. 2014;15:58.
25. Lopez-Briz E, Ruiz-Garcia V, Carbonell-Sanchis R. Re: Polypharmacy: a necessary evil. BMJ. 2013;347:f7033.
26. The King’s Fund. Polypharmacy and medicines optimisation: making it safe and sound. London; 2013. Available from: http://www.kingsfund.org.uk/sites/files/kf/field/field_publication_file/polypharmacy-and-medicines-optimisation-kingsfund-nov13.pdf. Accessed 13 Dec 2015.
27. Belfrage B, Koldestam A, Sjöberg C, Wallerstedt SM. Number of drugs in the medication list as an indicator of prescribing quality: a validation study of polypharmacy indicators in older hip fracture patients. Eur J Clin Pharmacol. 2015;71(3):363–8.
28. Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol. 2007;63(2):187–95.
29. Carey IM, De Wilde S, Harris T, Victor C, Richards N, Hilton SR, et al. What factors predict potentially inappropriate primary care prescribing in older people? Analysis of UK primary care patient record database. Drugs Aging. 2008;25(8):693–706.
30. Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72–83.
31. Broekhuizen K, Pothof A, de Craen AJM, Mooijaart SP. Characteristics of randomized controlled trials designed for elderly: a systematic review. PLoS One. 2015;10:e0126709.
32. Hughes LD, McMurdo MET, Guthrie B. Guidelines for people not for diseases: the challenges of applying UK clinical guidelines to people with multimorbidity. Age Ageing. 2013;42(1):62–9.
33. Scottish Government Model of Care Polypharmacy Working Group. Polypharmacy guidance (2nd edition). Scotland; 2015. Available from: http://www.sign.ac.uk/pdf/polypharmacy_guidance.pdf. Accessed 13 Dec 2015.
34. Ickowicz E. Patient-centered care for older adults with multiple chronic conditions: a stepwise approach from the American Geriatrics society. J Am Geriatr Soc. 2012;60(10):1957–68.
35. National Institute for Health and Care Excellence. Multimorbidity: assessment, prioritisation and management of care for people with commonly occurring multimorbidities. Available from: https://www.nice.org.uk/guidance/indevelopment/gid-cgwave0704. Accessed 13 Dec 2015.
36. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37–43.
37. Cooper JA, Ryan C, Smith SM, Wallace E, Bennett K, Cahir C, et al. The development of the PROMPT (PRescribing Optimally in Middle-aged People’s Treatments) criteria. BMC Health Serv Res. 2014;14:484.
38. Moriarty F, Hardy C, Bennetta K, Smith S, Fahey T. Trends in polypharmacy and prescribing appropriateness from 1997 to 2012. Int J Pharm Pract. 2015;23(S1):24–5.
39. Cahir C, Moriarty F, Teljeur C, Fahey T, Bennett K. Potentially inappropriate prescribing and vulnerability and hospitalization in older community-dwelling patients. Ann Pharmacother. 2014;48(12):1546–54.
40. National Institute for Health and Care Excellence. NICE guidelines [NG5]: medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes. United Kingdom; 2015. Available from: https://www.nice.org.uk/guidance/ng5. Accessed 13 Dec 2015.
41. Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827–34.
42. Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD. The benefits and harms of deprescribing. Med J Aust. 2014;201(7):386–9.
43. Scott IA, Anderson K, Freeman CR, Stowasser DA. First do no harm: a real need to deprescribe in older patients. Med J Aust. 2014;201(7):390–2.
44. Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD. Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. Br J Clin Pharmacol. 2014;78(4):738–47.
45. Reeve E, Wiese MD. Benefits of deprescribing on patients’ adherence to medications. Int J Clin Pharm. 2014;36(1):26–9.
46. Fried TR, O’Leary J, Towle V, Goldstein MK, Trentalange M, Martin DK. Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review. J Am Geriatr Soc. 2014;62(12):2261–72.
47. George J, Phun YT, Bailey MJ, Kong DCM, Stewart K. Development validation of the medication regimen complexity index. Ann Pharmacother. 2004;38(9):1369–76.
48. De Cates Angharad N, Farr Matthew RB, Wright N, Jarvis Morag C, Rees K, Ebrahim S, et al. Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst Rev. 2014;4:CD009868.
49. Mansur N, Weiss A, Beloosesky Y. Looking beyond polypharmacy: quantification of medication regimen complexity in the elderly. Am J Geriatr Pharmacother. 2012;10(4):223–9.
50. Conn VS, Hafdahl AR, Cooper PS, Ruppar TM, Mehr DR, Russell CL. Interventions to improve medication adherence among older adults: meta-analysis of adherence outcomes among randomized controlled trials. Gerontologist. 2009;49(4):447–62.
51. O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2014;44(2):213–8.
52. Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, et al. Developing core outcome sets for clinical trials: issues to consider. Trials. 2012;13:132.
53. Prinsen CAC, Vohra S, Rose MR, King-Jones S, Ishaque S, Bhaloo Z, et al. Core Outcome Measures in Effectiveness Trials (COMET) initiative: protocol for an international Delphi study to achieve consensus on how to select outcome measurement instruments for outcomes included in a “core outcome set”. Trials. 2014;15:247.